Cases of secondary tumors have been reported as a possible adverse reaction to the treatment of certain blood cancers with CAR T-cells. A recent analysis of the cases reported to the ...

Cancer cells can poison attacking immune cells by filling them with defective mitochondria ― dampening the body’s defensive forces and helping the tumour to evade eradication 1. These findings ...

This new study finds that a unique population of T cells found in patients who are responding to DLI might be the key. These cells fight leukemia by boosting the immune response. Additionally ...

Innate immune ... dendritic cells collect and synthesize cholesterol to construct lipid nanodomains on their membranes. Obstructing this process impairs their ability to prime T cells.

That means their immune systems have built up some level of immunity against common influenza viruses. Sette and Grifoni investigated how well these influenza-fighting T cells might recognize and ...

CAR T cell therapy, first developed at Penn Medicine, is a personalized cancer treatment that reprograms a patient’s immune cells to target and destroy cancer cells. “Thousands of patients with blood ...

This case of a successful treatment of multi-refractory primary immune thrombocytopenia adds to the growing body of evidence supporting the use of CD19 CAR T-cell therapy in B cell-driven autoimmune ...

T lymphocytes (T cells) and B lymphocytes (B cells) are two types of white blood cells that perform immune functions in the lymphatic system. B-cells produce antibodies to attack bacteria and viruses ...

Sep. 4, 2024 — Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is ...

Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T ...

The autologous TCR T-cell therapy is indicated for patients with MAGE-A4-expressing synovial sarcoma who test positive for the human leukocyte antigen types HLA A*02:01P, HLA A*02:02P, HLA A*02:03P, ...

These non-viral vectors can be engineered for precision in delivering CAR constructs to specific immune cells, fostering a scalable, safer method for CAR T-cell production that could be feasible in a ...